Cumberland Pharmaceuticals (CPIX) Tops Q4 EPS by 2c, Revenues Beat
Get Alerts CPIX Hot Sheet
Join SI Premium – FREE
Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q4 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $10.26 million versus the consensus estimate of $9.78 million.
"We are grateful that Cumberland was able to successfully manage through the pandemic during 2020, in spite of the significant market headwinds and other challenges we encountered," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Our facilities remained open, our operations continued, and our organization remained intact." He continued, "I would like to acknowledge and thank my colleagues for their continued dedication during such trying times for many. Together, we remain focused on our mission of advancing patient care through the delivery of high-quality medicines."
For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
- Shimmick Corporation (SHIM) Misses Q4 EPS by 38c ; Provides Outlook
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!